Divi's Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 11, 2025. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

Divi's Laboratories held its 35th AGM on August 11, 2025, through video conferencing, with 176 members participating. All six resolutions were passed with the required majority, including adoption of FY25 financial statements, declaration of a ₹30 per share dividend (1,500%), re-appointment of two directors, appointment of secretarial auditors, and approval for enhanced remuneration of a related party. For FY25, the company reported consolidated total income of ₹9,712 crores, profit after tax of ₹2,191 crores, and EPS of ₹82.53, with exports making up 88% of revenue. Q1 FY26 results showed total income of ₹2,529 crores and PAT of ₹545 crores. Key operational highlights included the start of Phase I commercial production at the new Unit-3 facility in Kakinada (200-acre greenfield site) and a successful US FDA cGMP inspection at Unit-2, Visakhapatnam. The company is investing in peptide API manufacturing, continuous flow chemistry, and custom synthesis to tap into the high-growth GLP-1 segment.